Welcome to the Current Issues section of the Journal of Transitional Pharmaceutical Care (JTPC). This page provides full access to our latest publications as well as previous issues, ensuring our readers and researchers stay informed on the evolving landscape of pharmaceutical care across care transitions.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Engineered Nanoscale Delivery Platforms for Site-Specific Transport of Anticancer Phytochemicals
Vol.2(1); Pages:1-9. Published on April-2026
Abstract
The application of nanocarrier systems in targeted drug delivery has revolutionized cancer therapeutics by enhancing drug bioavailability and minimizing systemic toxicity. This study investigates the efficacy of biodegradable polymeric nanoparticles encapsulating plant-derived anticancer compounds, specifically curcumin and resveratrol. The nanoparticles were synthesized using a solvent evaporation technique and characterized for size, zeta potential, and encapsulation efficiency. In vitro cytotoxicity assays were conducted on human breast cancer cell lines, followed by in vivo evaluation in murine tumor models. Results demonstrated significantly improved cellular uptake and sustained drug release compared to free drug formulations. Tumor regression rates increased by 45% in treated groups, with reduced adverse effects. Histopathological analysis confirmed targeted accumulation in tumor tissues. The findings highlight the potential of nanocarrier-based phytochemical delivery systems as a promising alternative to conventional chemotherapy, offering enhanced therapeutic precision and patient safety.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Engineering Genetic Corrections in Rare Metabolic Diseases Using CRISPR Platforms
Vol.2(1); Pages:10-18. Published on May-2026
Abstract
Rare metabolic disorders often lack effective treatments due to their genetic complexity and low prevalence. This study explores the application of CRISPR-Cas9 gene editing technology to correct mutations associated with phenylketonuria (PKU). Patient-derived induced pluripotent stem cells (iPSCs) were edited using a guide RNA targeting the PAH gene mutation. Post-editing analyses included genomic sequencing, enzyme activity assays, and metabolic profiling. The corrected cells demonstrated restored phenylalanine hydroxylase activity and normalized metabolic function. Furthermore, differentiation into hepatocyte-like cells confirmed sustained gene correction without off-target effects. In vivo validation using a murine PKU model showed significant reduction in phenylalanine levels. These findings suggest that CRISPR-based therapies hold substantial promise for treating inherited metabolic disorders, paving the way for personalized and curative interventions.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Algorithmic Identification of Repurposable Therapeutics for Neurodegenerative Disease Care
Vol.2(1); Pages:19-27. Published on May-2026
Abstract
Repurposing of drugs has also become a cost effective option in finding new applications of existing drugs. This research will use artificial intelligence (AI) algorithms to select possible drug candidates to treat Alzheimer disease. Pharmacological databases, gene expression profiles, and clinical trial data were used to train a machine learning model to determine drug-disease interactions. In the model, five drugs that had high repurposing potential and were approved by FDA were shortlisted. Neuroprotective effects were shown by two of these candidates in subsequent in vitro validation of neuronal cell cultures, which strongly inhibited amyloid beta aggregation and oxidative stress indicators. Molecular docking research also established high binding affinities with key targets of disease Alzheimer. The use of AI in drug discovery improves the speed of the identification process and predictive accuracy. It provides a flexible model that can be used to treat complicated neurodegenerative illnesses using novel treatment methods.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Engineered Biodegradable Hydrogel Matrices for Sustained Anti Inflammatory Delivery in Chronic Wounds
Vol.2(1); Pages:28-36. Published on June-2026
Abstract
Chronic wounds present a significant clinical challenge due to prolonged inflammation and delayed healing. This study evaluates the efficacy of biodegradable hydrogel systems for the controlled release of anti inflammatory drugs. Hydrogels composed of chitosan and polyethylene glycol were synthesized and loaded with diclofenac sodium. The release kinetics were assessed under simulated physiological conditions, demonstrating a sustained release over 72 hours. In vitro assays using human dermal fibroblasts indicated enhanced cell proliferation and reduced inflammatory cytokine expression. A simulated wound environment model further confirmed accelerated tissue regeneration. The hydrogels exhibited excellent biocompatibility and mechanical stability, making them suitable for topical application. These findings support the potential of hydrogel-based delivery systems in improving chronic wound management and patient outcomes.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Lipid Nanocarrier Strategies for Enabling Oral Insulin Transport Across Gastrointestinal Barriers
Vol.2(1); Pages:37-44. Published on June-2026
Abstract
Oral delivery of insulin remains a significant challenge due to enzymatic degradation and poor intestinal absorption. This study investigates lipid-based nanoparticles as a viable strategy for oral insulin administration. Solid lipid nanoparticles (SLNs) were formulated using glyceryl monostearate and stabilized with surfactants. Encapsulation efficiency and particle stability were evaluated, followed by in vitro digestion and permeability studies using Caco-2 cell models. The SLNs demonstrated high encapsulation efficiency and protection against enzymatic degradation. Permeability assays indicated enhanced translocation across intestinal epithelial cells. In vivo studies in diabetic rat models showed a significant reduction in blood glucose levels, comparable to subcutaneous insulin administration. The formulation exhibited prolonged hypoglycemic effects, indicating sustained release. These results highlight the promise of lipid-based carriers in transforming insulin therapy, potentially improving patient compliance and quality of life.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
